Arcutis Biotherapeutics Says FDA Approved Its ZORYVE (roflumilast) Cream 0.3% For Treatment Of Psoriasis In Children Ages 6 To 11
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Arcutis Biotherapeutics' supplemental new drug application (sNDA) to expand the indication of ZORYVE (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis in children aged 6 to 11 years.
October 06, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA approval of Arcutis Biotherapeutics' sNDA for ZORYVE cream 0.3% could potentially increase the company's market share and revenues by expanding its product's target demographic.
The FDA approval allows Arcutis Biotherapeutics to expand the use of its ZORYVE cream to children aged 6 to 11 years. This could potentially increase the company's market share and revenues as it can now target a wider demographic. The news is highly relevant and important for the company and could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100